Skip to main content

Peer Review reports

From: Real-world long-term efficacy and safety of erenumab in adults with chronic migraine: a 52-week, single-center, prospective, observational study

Original Submission
6 May 2022 Submitted Original manuscript
10 May 2022 Reviewed Reviewer Report
11 May 2022 Reviewed Reviewer Report - Julia Azimova
20 May 2022 Author responded Author comments - Faisal Mohammad Amin
Resubmission - Version 2
20 May 2022 Submitted Manuscript version 2
20 May 2022 Editorially accepted
2 Jun 2022 Article published 10.1186/s10194-022-01433-9

You can find further information about peer review here.

Back to article page